Made With Uberflip Content Marketing

partneringNEWS

Insights for the life science partnering community

  • Starting a biotech company: What every entrepreneur needs to know

    Just released: The Biotech Startup Manual. This report distills the insights, wisdom, and inspiration from a carefully selected group of industry pioneers on what it truly takes to start a...

    Read
  • How stakeholder insight adds value to your asset and drug development program

    How stakeholder insight adds value to your asset and drug development program

    Thinking early about market access is something many small and virtual biotech firms don’t automatically think to do, but should. Read more »

    Read
  • Where are they now? EpiAxis Therapeutics channels successes into scientific and business development

    Where are they now? EpiAxis Therapeutics channels successes into scientific and business development

    EpiAxis Therapeutics is channeling its success at BioPharm America™’s Startup Day into success at the business and scientific levels. Since finishing first for best “investment pitch quality and...

    Read
  • Where are they now? For Virvio, it’s all about visibility

    Where are they now? For Virvio, it’s all about visibility

    When Virvio participated in BioPharm America™’s Startup Day pitch contest in 2016, the company had been operational less than one year. It had three employees and was operating under grants from...

    Read
  • Where are they now? Cocoon Biotech planning tox studies

    Where are they now? Cocoon Biotech planning tox studies

    Recognition from a high profile organization like the BioPharm America™ conference has been tremendous for Cocoon,” Ailis Tweed-Kent, MD, founder and CEO of Cocoon Biotech says. Winning the...

    Read
  • Startup Slam: Compelling pitch for Peptomyc takes the prize

    Startup Slam: Compelling pitch for Peptomyc takes the prize

    The third round of this fast-paced parade of presentations pitted 14 promising entrepreneurs in a winner-take-all competition. The reward includes tailored mentoring with the scientists and...

    Read
  • POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    POLs: Patient opinion leaders emerge as key to success in orphan drug designation

    Orphan drugs are wicked hot. Wall Street loves them. And patients are a powerful force that can make or break a decision to grant that coveted designation for your drug. But don't count on having...

    Read
  • Biotechs successfully navigate alternative paths to financing

    Biotechs successfully navigate alternative paths to financing

    Project awards, strategic venture funds and now crowd-funding offer alternatives to traditional venture funds for emerging biotech companies. Pfizer's new strategic fund or the well-established...

    Read
  • Digital medicine takes small steps toward Big Data

    Digital medicine takes small steps toward Big Data

    Across a fragmented European landscape multiple programs advance the digitization of data as building blocks for advanced analytics. Read more »

    Read
  • Facing increased complexity, oncology trial sites tighten up procedures

    Facing increased complexity, oncology trial sites tighten up procedures

    Financing a Phase I trial in oncology is tough, but completing a successful trial for a novel drug candidate is even tougher. An army of specialists is required, and then comes the challenge of...

    Read
  • Can pharma afford to cure patients instead of treating them?

    Can pharma afford to cure patients instead of treating them?

    Who wants a one-shot therapy that delivers a durable response in patients? What is the price for a cure that payers are willing to pay? Why is pharma turning its attention away from this...

    Read
  • BIO Report: Funding cools down after five-year run while early deals stay hot

    BIO Report: Funding cools down after five-year run while early deals stay hot

    Across five metrics for biotech financings tracked by BIO, the sector saw steep drops in 2016 due to uncertainty introduced by political upheavals and regulatory reforms. Yet in each category the...

    Read
  • Mounting uncertainty threatens research and innovation in medicines

    Mounting uncertainty threatens research and innovation in medicines

    Regulatory reforms, political upheavals and proposed cuts to research funding create an uncertain and increasingly risky landscape for companies developing new medicines. The life sciences...

    Read
  • Rexgenero readies cell therapy for Critical Limb Ischemia Phase III

    Rexgenero CEO Dr. Joe Dupere says that the London-based cell therapy company is seeking new investors and potential partners for Asian and Middle Eastern markets. Read more »

    Read
  • VIDEO: Innovation in an uncertain world

    VIDEO: Innovation in an uncertain world

    How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? Read more »

    Read
  • Chinese capital accesses Western innovation to create homegrown industry

    Tony Chu, co-founder and managing partner at consultants TPP Healthcare, how Chinese capital is accessing Western innovation to build a PRC pharma industry. Read more »

    Read
  • Rare diseases, rare commitment

    Rare diseases, rare commitment

    Patients, their families and patient foundations are invaluable in helping drug developers understand the day-to-day realities of approx. 7,000 rare diseases (of which only 400 have therapies)....

    Read
  • Breaking news:  Creating a healthcare futures market

    Breaking news: Creating a healthcare futures market

    Dennis Purcell, founder and senior advisor of Aisling Capital LLC, and co-founder of Poliwogg, is creating a futures market for healthcare, mirroring healthcare consumption from diagnosis to...

    Read
  • Peter Fong on Genentech’s science shopping list, recent BioNtech deal

    Peter Fong on Genentech’s science shopping list, recent BioNtech deal

    Peter Fong explains Genentech's oncology focus, seeking the best science and how a typical biotech deal works for the company. Read more » Related Posts BioNTech’s Sean Marett explains Genentech...

    Read
  • eTheRNA CEO outlines development plan in cancer RNA space

    eTheRNA CEO outlines development plan in cancer RNA space

    Mike Ward interviews Dirk Reyn, CEO of eTheRNA, discussing eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company. Read more » Related...

    Read
  • loading
    Loading More...